ACERUS OTC Stock Today

ASPCF -  USA Stock  

USD 0.0236  0.0036  18.00%

Market Performance
1 of 100
Odds Of Distress
Over 70
ACERUS PHARMACEUTICALS is trading at 0.0236 as of the 24th of January 2022, a 18.00 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0236. ACERUS PHARMACEUTICALS has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for ACERUS PHARMACEUTICALS CORP are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2021 and ending today, the 24th of January 2022. Click here to learn more.
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for mens and womens health. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. The company has 1.54 B outstanding shares. More on ACERUS PHARMACEUTICALS CORP
Follow Valuation Odds of Bankruptcy
Check how we calculate scores


Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. ACERUS PHARMACEUTICALS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ACERUS PHARMACEUTICALS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ACERUS PHARMACEUTICALS has very high historical volatility over the last 90 days
ACERUS PHARMACEUTICALS has some characteristics of a very speculative penny stock
ACERUS PHARMACEUTICALS has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 17.01 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. ACERUS PHARMACEUTICALS has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported the revenue of 1.65 M. Net Loss for the year was (31.9 M) with loss before overhead, payroll, taxes, and interest of (929 K).
ACERUS PHARMACEUTICALS CORP has accumulated about 2.27 M in cash with (21.34 M) of positive cash flow from operations.
Roughly 91.0% of ACERUS PHARMACEUTICALS shares are held by company insiders
Latest headline from Hormones Market Research Report by Type, by Route of administration, by End-User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 - Yahoo Finance
President CEO, DirectorEdward Gudaitis  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of ACERUS PHARMACEUTICALS's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
ACERUS PHARMACEUTICALS CORP [ASPCF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with current market capitalization of 36.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ACERUS PHARMACEUTICALS's market, we take the total number of its shares issued and multiply it by ACERUS PHARMACEUTICALS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. ACERUS PHARMACEUTICALS classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 1.54 B outstanding shares. ACERUS PHARMACEUTICALS CORP has accumulated about 2.27 M in cash with (21.34 M) of positive cash flow from operations.
Check ACERUS PHARMACEUTICALS Probability Of Bankruptcy
ACERUS PHARMACEUTICALS holds a total of one billion five hundred fourty million outstanding shares. ACERUS PHARMACEUTICALS shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 91.37 percent of ACERUS PHARMACEUTICALS outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how much assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check ACERUS Ownership Details

ACERUS Stock Price Odds Analysis

What are ACERUS PHARMACEUTICALS's target price odds to finish over the current price? Based on a normal probability distribution, the odds of ACERUS PHARMACEUTICALS jumping above the current price in 90 days from now is about 64.7%. The ACERUS PHARMACEUTICALS CORP probability density function shows the probability of ACERUS PHARMACEUTICALS otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon ACERUS PHARMACEUTICALS CORP has a beta of -3.0744. This suggests as returns on its benchmark rise, returns on holding ACERUS PHARMACEUTICALS CORP are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, ACERUS PHARMACEUTICALS is expected to outperform its benchmark. Additionally, the company has an alpha of 0.1892, implying that it can generate a 0.19 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 0.0236HorizonTargetOdds Up 0.0236 
35.21%90 days
Based on a normal probability distribution, the odds of ACERUS PHARMACEUTICALS to move above the current price in 90 days from now is about 64.7 (This ACERUS PHARMACEUTICALS CORP probability density function shows the probability of ACERUS OTC Stock to fall within a particular range of prices over 90 days) .


Investors will always prefer to have the highest possible return on investment while minimizing volatility. ACERUS PHARMACEUTICALS market risk premium is the additional return an investor will receive from holding ACERUS PHARMACEUTICALS long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ACERUS PHARMACEUTICALS. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although ACERUS PHARMACEUTICALS's alpha and beta are two of the key measurements used to evaluate ACERUS PHARMACEUTICALS's performance over the market, the standard measures of volatility play an important role as well.

ACERUS Stock Against Markets

Picking the right benchmark for ACERUS PHARMACEUTICALS otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ACERUS PHARMACEUTICALS otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ACERUS PHARMACEUTICALS is critical whether you are bullish or bearish towards ACERUS PHARMACEUTICALS CORP at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in ACERUS PHARMACEUTICALS without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamental Analysis Now


Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module


ACERUS PHARMACEUTICALS corporate directors refer to members of an ACERUS PHARMACEUTICALS board of directors. The board of directors generally takes responsibility for the ACERUS PHARMACEUTICALS's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ACERUS PHARMACEUTICALS's board members must vote for the resolution. The ACERUS PHARMACEUTICALS board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Josef Vejvoda - DirectorProfile
Borys Chabursky - DirectorProfile
Mark Lievonen - DirectorProfile
Stephen Gregory - Lead Independent DirectorProfile
Please continue to Trending Equities. Note that the ACERUS PHARMACEUTICALS information on this page should be used as a complementary analysis to other ACERUS PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for ACERUS OTC Stock analysis

When running ACERUS PHARMACEUTICALS price analysis, check to measure ACERUS PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACERUS PHARMACEUTICALS is operating at the current time. Most of ACERUS PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of ACERUS PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ACERUS PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of ACERUS PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is ACERUS PHARMACEUTICALS's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACERUS PHARMACEUTICALS. If investors know ACERUS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACERUS PHARMACEUTICALS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ACERUS PHARMACEUTICALS is measured differently than its book value, which is the value of ACERUS that is recorded on the company's balance sheet. Investors also form their own opinion of ACERUS PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is ACERUS PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACERUS PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect ACERUS PHARMACEUTICALS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACERUS PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine ACERUS PHARMACEUTICALS value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACERUS PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.